Mouse Anti-CECR2 Recombinant Antibody (CBWJC-2465) (CBMAB-C3533WJ)

Wu, L., Zhao, G., Xu, S., Kuang, J., Ming, J., Wu, G., ... & Liu, J. (2021). The nuclear factor CECR2 promotes somatic cell reprogramming by reorganizing the chromatin structure. Journal of Biological Chemistry, 296.

Wang, X., Xu, C., Wang, S., Huang, W., Liu, Y., Zhang, X., ... & Liu, F. (2021). A novel tumor suppressor CECR2 down regulation links glutamine metabolism contributes tumor growth in laryngeal squamous cell carcinoma. Clinical and Translational Oncology, 1-13.

Park, S. G., Lee, D., Seo, H. R., Lee, S. A., & Kwon, J. (2020). Cytotoxic activity of bromodomain inhibitor NVS-CECR2-1 on human cancer cells. Scientific reports, 10(1), 1-15.

Zhang, M., Liu, Z., Aoshima, K., Zhang, Y., An, Y., Aoshima, A., ... & Yan, Q. (2020). CECR2 Drives Breast Cancer Metastasis by Suppressing Macrophage Inflammatory Responses. bioRxiv.

Lucas, S. C., Atkinson, S. J., Bamborough, P., Barnett, H., Chung, C. W., Gordon, L., ... & Demont, E. H. (2020). Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding Mode. Journal of medicinal chemistry, 63(10), 5212-5241.

Crawford, T. D., Audia, J. E., Bellon, S., Burdick, D. J., Bommi-Reddy, A., Côté, A., ... & Cochran, A. G. (2017). GNE-886: a potent and selective inhibitor of the cat eye syndrome chromosome region candidate 2 bromodomain (CECR2). ACS medicinal chemistry letters, 8(7), 737-741.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Isotype control